• ABT-888 (Veliparib): Precision PARP Inhibition for Translati

  2026-05-18

  This thought-leadership article explores how ABT-888 (Veliparib), a potent PARP1/2 inhibitor, advances translational cancer research by enabling precise DNA repair inhibition and enhancing the efficacy of chemotherapy and radiation—especially in microsatellite instability (MSI) tumor models. We discuss mechanistic insights, protocol guidance, and the strategic landscape for integrating ABT-888 into preclinical workflows, referencing both current literature and product intelligence from APExBIO.

• Ganetespib (STA-9090): Streamlined Hsp90 Inhibition Workflow

  2026-05-18

  Ganetespib (STA-9090) empowers cancer research with potent, selective Hsp90 inhibition, enabling rapid client protein degradation and robust tumor growth inhibition across diverse models. Learn how to optimize experimental design, troubleshoot common challenges, and leverage recent mechanistic insights to maximize data quality and translational relevance.

• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB): Mechani

  2026-05-17

  5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is a potent transcriptional elongation inhibitor with established efficacy in inhibiting cyclin-dependent kinases and RNA polymerase II-mediated transcription. DRB demonstrates robust inhibition of HIV transcription and influenza virus replication in vitro. Its high-purity formulation from APExBIO supports reproducible molecular biology workflows.

• Streptavidin-Cy3: Precision Biotin Detection for Advanced As

  2026-05-16

  Streptavidin-Cy3 from APExBIO offers unmatched sensitivity and reliability for biotin detection across immunohistochemistry, immunofluorescence, and in situ hybridization workflows. Its robust Cy3 fluorescence and high-affinity streptavidin-biotin interaction streamline experimental design, empowering researchers to visualize subtle biomolecular interactions—even in complex cancer metastasis studies.

• Nimbolide Targets RNF114 to Induce PARP1 Trapping in BRCA-Mu

  2026-05-15

  Li et al. identify the E3 ubiquitin ligase RNF114 as a regulator of PARP1 removal from DNA lesions and show that nimbolide, a natural product, inhibits RNF114, leading to persistent PARP1 trapping and synthetic lethality in BRCA-mutated cancer cells. This mechanism offers a novel strategy to overcome resistance to PARP inhibitors and informs DNA damage response research.

• D-Luciferin in Bioluminescence Imaging: Workflows & Innovati

  2026-05-15

  D-Luciferin, the gold-standard firefly luciferase substrate, powers highly sensitive, non-invasive bioluminescence imaging and precise intracellular ATP quantification. This article details stepwise experimental workflows, troubleshooting strategies, and cutting-edge research applications, leveraging APExBIO’s high-purity D-Luciferin to maximize data quality and translational impact.

• ORM2 Modulates Autophagy to Alleviate Pancreatic Fibrosis in

  2026-05-14

  A recent study uncovers that ORM2, an acute-phase protein, mitigates pancreatic fibrosis in chronic pancreatitis by suppressing autophagy-driven activation of pancreatic stellate cells through ZG16 binding. This mechanistic insight highlights ORM2 as a promising candidate for anti-fibrotic interventions and advances our understanding of autophagy’s role in digestive disease progression.

• Tropifexor (LJN452): FXR Modulation for Barrier & Disease Mo

  2026-05-14

  Tropifexor (LJN452) stands out as a next-generation FXR signaling pathway modulator, enabling advanced research on intestinal epithelial barrier function and metabolic disease models. This guide provides actionable protocols, troubleshooting, and data-driven insights for maximizing experimental reproducibility with APExBIO’s Tropifexor.

• Boosting Assay Sensitivity with Cy3 Goat Anti-Human IgG (H+L

  2026-05-13

  The Cy3 Goat Anti-Human IgG (H+L) Antibody delivers reliable, high-sensitivity detection of human immunoglobulins across immunofluorescence, immunohistochemistry, flow cytometry, and ELISA. Its robust signal amplification and minimal cross-reactivity make it a trusted tool for researchers demanding precision and reproducibility.

• HotStart Universal 2X Green qPCR Master Mix for Stemness Ass

  2026-05-13

  APExBIO’s HotStart™ Universal 2X Green qPCR Master Mix delivers robust, reproducible gene expression quantification in even the most challenging cancer stemness and metastasis research. Its hot-start Taq polymerase and universal ROX compatibility streamline workflows, while integrated Green I dye enables precise DNA amplification monitoring and melt curve specificity assessment.

• ML-7 Hydrochloride: Optimizing MLCK Inhibition Workflows

  2026-05-12

  ML-7 hydrochloride is a selective myosin light chain kinase inhibitor that empowers researchers to dissect MLCK-mediated pathways in cardiovascular and cancer models. This article translates recent mechanistic breakthroughs and protocol best practices into actionable strategies, spotlighting APExBIO’s ML-7 hydrochloride for robust translational research.

• Gingerenone A Restores Sunitinib Sensitivity in RCC via LDHA

  2026-05-12

  This study identifies gingerenone A as a metabolic inhibitor that suppresses LDHA-mediated glycolysis, disrupts HIF-1α signaling, and restores sensitivity to sunitinib in renal cell carcinoma. These findings suggest a promising metabolic-adjuvant strategy to combat drug resistance in RCC.

• Bispecific Anti-M1R/B6R Antibodies Enhance Orthopoxvirus Pro

  2026-05-11

  This study systematically characterizes monoclonal antibodies targeting the major mpox virus antigens M1R and B6R and introduces a bispecific antibody format with superior neutralizing and protective efficacy in preclinical models. These findings refine our understanding of orthopoxvirus immune targeting and support next-generation antibody therapeutic development.

• 5-HT3 Antagonists Inhibit Renal OCT2 and MATE1: In Vitro Ins

  2026-05-11

  This study delineates the inhibitory effects of several antiemetic 5-HT3 receptor antagonists, including tropisetron, on renal organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1) in vitro. The findings highlight potential implications for drug-drug interactions and cationic drug pharmacokinetics, providing foundational data for researchers in transporter and neuropharmacology fields.

• Gepotidacin: Redefining Strategies in Antibacterial Research

  2026-05-10

  This thought-leadership article explores the mechanistic innovation and translational potential of Gepotidacin (GSK2140944), a first-in-class triazaacenaphthylene antibiotic. We provide strategic guidance for translational researchers, spanning its unique mechanism, experimental best practices, clinical pharmacokinetics, and the broader impact on antibiotic resistance research. The piece offers a perspective not found in standard product overviews, integrating protocol recommendations and forward-looking insights for the next phase of antibacterial drug development.

496 records 14/34 page Previous Next First page 上5页 1112131415 下5页 Last page